Stock DNA
Pharmaceuticals & Biotechnology
INR 218 Cr (Micro Cap)
12.00
40
0.00%
0.18
7.79%
0.95
Total Returns (Price + Dividend) 
Gennex Lab. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Gennex Laboratories Ltd is Rated Sell
Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Gennex Laboratories Ltd is Rated Sell
Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 November 2026, providing investors with the most up-to-date view of the company’s performance and outlook.
Read More
Gennex Laboratories Ltd is Rated Sell
Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-2026 | Source : BSEPursuant to regulation 47 of SEBI (LODR) Regulations 2015 please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2026 announced by the Board of Directors in its meeting held on Saturday November 14 2026. Financial results had been published in both Business Standard (English) and Saksham (Telugu - Local) on November 17 2026.
Intimation Regarding Dissolution Of The Rights Issue Committee Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
14-Nov-2026 | Source : BSEPursuant to Regulation 30 read with Schedule III of the SEBI (LODR) Regulations 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. November 14 2026 has approved the dissolution of the Rights Issue Committee with immediate effect i.e. November 14 2026.
Board Meeting Outcome for Meeting Held Today I.E. 30Th September 2026
14-Nov-2026 | Source : BSE1. Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2026 along with the Statement of Assets and Liabilities as at September 30 2026 and the Statement of Cash Flows for the half year ended September 30 2026 (annexed herewith);
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
Gennex Laboratories Ltd has announced 1:10 stock split, ex-date: 14 Dec 09
No Bonus history available
Gennex Laboratories Ltd has announced 1:2 rights issue, ex-date: 21 Jul 22
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
21.7749
Held by 0 Schemes
Held by 0 FIIs
Premier Fiscal Services Private Limited (21.83%)
Jms Mines & Minerals Private Limited (3.25%)
56.3%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 7.53% vs 17.74% in Sep 2025
YoY Growth in quarter ended Sep 2026 is -17.89% vs 4.14% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 11.30% vs 85.46% in Sep 2024
Growth in half year ended Sep 2025 is -4.09% vs 69.43% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 9.79% vs 86.07% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 1.30% vs 72.39% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 25.26% vs 50.51% in Mar 2025
YoY Growth in year ended Mar 2026 is 14.52% vs 30.84% in Mar 2025